Benzinga | Oct 25, 2021 04:10PM EDT

89bio Highlights Presentation Of New Sub-Analysis From Phase 1b/2a NASH Study Of BIO89-100 At American Association for the Study of Liver Diseases Nov. 14

89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that a sub-analysis of its Phase 1b/2a proof-of-concept study of BIO89-100 in non-alcoholic steatohepatitis (NASH) looking at the correlation of liver fat and spleen volume will be an oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021. A poster with new data on the population pharmacokinetics and pharmacodynamics of BIO89-100 will also be presented. The meeting will be held virtually November 12-15, 2021.

Both abstracts were published in the October supplement of AASLD's peer-reviewed journal, Hepatology. The presentations will also be available on the 89bio website after the meeting.

Presentation details are as follows:

Abstract Title: Treatment with BIO89-100 Led to Decreased Spleen Volume That was Correlated with Relative Change in Liver Fat Volume and Pro-C3 Level in a Phase 1b/2a, Placebo-controlled, Double-blind, NASH Proof of Concept (POC) Study

Abstract Number: 139

Presenting Author: Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego

Session Title: Parallel 21: NAFLD and NASH: Clinical Trials of Novel Therapeutics

Presentation Date and Time: Sunday, November 14th 6:30-8:00 PM / EST

Abstract Title: Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of BIO89-100, a Novel GlycoPegylated FGF21, in a Phase 1b/2a POC Study in Nonalcoholic Steatohepatitis (NASH)

Abstract Number: 1931

Presenting Author: Leo Tseng, PHD, 89bio Clinical Development

Session Title: NAFLD and NASH: Therapeutics - Pharmacologic and Other.